10.1016/j.jpha.2023.07.001 [DOI] [PMC free article] [PubMed] [Google Scholar] 119.Venkataraman B, Almarzooqi S, Raj V, Bhongade BA, Patil RB, Subramanian VS, Attoub S, Rizvi TA, Adrian TE, Subramanya SB
MT-II was designed and characterised through the systematic melanocortin peptide structure-activity relationship programme in Victor Hrubys laboratory at the University of Arizona , the same programme that produced MT-1 , with the cyclisation strategy introduced to further constrain the pharmacophore into a receptor-binding conformation that simultaneously increases potency, metabolic stability, and the receptor subtype selectivity profile that distinguishes MT-II from the linear tridecapeptide MT-1
Easier mornings after hard lifting daysCHECK
Sophora flavescens alkaloids and corticosteroid synergistically augment IL-10/IL-5 ratio with Foxp3-gene-epigenetic modification in asthma PBMCs